# Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury

> **NCT05951777** · PHASE2 · RECRUITING · sponsor: **Hope Biosciences LLC** · enrollment: 51 (estimated)

## Conditions studied

- Traumatic Brain Injury

## Interventions

- **BIOLOGICAL:** Autologous HB-adMSCs
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT05951777
- **Lead sponsor:** Hope Biosciences LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-16
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2025-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05951777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05951777, "Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05951777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*